Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BMY vs NVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BMY Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

BMY Overall Winner 6-Pillar Tally: BMY 3 – 3 NVS Matrix Metrics: BMY 6 – 4 NVS

As of Nov 16, 2026, Bristol-Myers Squibb Co. (BMY) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). BMY carries a Unified Composite Score of 57.3/100 (HOLD) at $63.30 (9.5x Forward P/E, 32.4% operating margin), whereas NVS carries 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMY vs NVS
BMY NYSE Head-to-Head Winner
Bristol-Myers Squibb Co.
Pharmaceutical Preparations
$63.30
-0.21% 1D
Market Cap $127.4B
TTM Revenue $50.0B
Forward P/E 9.5x
Beta / 30D Vol 0.17β · 31% Vol
Unified Composite Score
57.3 / 100 HOLD
Tech 62.0 Fund 61.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 56
RSI-14: 55.7 · SMA20: $62.30 · SMA50: $61.83
NVS NYSE
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
TTM Revenue $40.5B
Forward P/E 16.2x
Beta / 30D Vol 0.31β · 27% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 61
RSI-14: 60.8 · SMA20: $159.19 · SMA50: $149.17

6-Pillar Scorecard Institutional Category Breakdown (BMY 3 – 3 NVS)

Columns: Metric · BMY · NVS
1. Valuation Multiples BMY
Forward P/E 9.5x 16.2x
Trailing P/E 13.8x 30.6x
PEG Ratio 17.25x 3.81x
EV / Revenue 3.3x 7.5x
2. Growth & Scale BMY
Revenue Growth (YoY) +6.9% +4.7%
Earnings Growth (YoY) -2.8% -68.8%
TTM Revenue (USD) $50.0B $40.5B
Market Cap $127.4B $302.9B
3. Profitability & Quality NVS
Gross Margin 70.5% 75.2%
Operating Margin 32.4% 34.0%
Net Profit Margin 18.5% 17.5%
Return on Equity (ROE) 44.0% 24.3%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $9.29B $17.0B EBITDA
Cash Flow Margin 18.6% 42.0% EBITDA Mgn
Net Cash / Leverage $35.2B Net Debt (1.91x D/E) $19.71 Book/Sh · 24.3% ROE
Dividend Yield 4.01% 2.96%
5. Options & Positioning BMY
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 82.3% (56th %ile) 16.9% (6th %ile)
Put/Call OI Skew 1.29x (Put-Skewed) Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat NVS
OpEx & R&D Intensity 38.1% of Rev ($19.1B) 41.2% of Rev ($16.7B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - General Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMY (6) vs NVS (4)
Institutional Metric BMY NVS Criterion Row Edge
Market Capitalization
Scale
$127.4B $302.9B Larger Scale NVS
Trailing P/E Ratio
Valuation
13.8x 30.6x Lower Multiple BMY
Forward P/E Ratio
Valuation
9.5x 16.2x Lower Multiple BMY
Revenue Growth (YoY)
Growth
+6.9% +4.7% Higher Growth BMY
Operating Margin (TTM)
Profitability
32.4% 34.0% Higher Margin NVS
Net Profit Margin
Profitability
18.5% 17.5% Higher Margin BMY
Return on Equity (ROE)
Capital Efficiency
44.0% 24.3% Higher ROE BMY
52-Week Range Position
Momentum
77% ($45–$69) 81% ($123–$170) Stronger Trend NVS
Beta / 30D Volatility
Risk Regime
0.17β · 31% Vol 0.31β · 27% Vol Lower Realized Risk NVS
Unified Institutional Score
Composite Signal
57.3 / 100 (HOLD) 41.5 / 100 (SELL) Higher Composite BMY
Trailing 12M Revenue (USD)
Operating Scale
$50.0B $40.5B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.5% 75.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
17.25x PEG · 3.3x EV/Rev 3.81x PEG · 7.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$9.29B ($35.2B Net Debt (1.91x D/E)) $17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NVS +1.35 pp
BMY: +5.93% · NVS: +7.28%
3M Horizon NVS +8.73 pp
BMY: -4.17% · NVS: +4.56%
6M Horizon BMY +2.1 pp
BMY: +10.44% · NVS: +8.34%
1Y Horizon BMY +7.66 pp
BMY: +30.16% · NVS: +22.5%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMY vs NVS. Trailing 12-month operating profitability (BMY 32.4% vs NVS 34.0%) and valuation multiples (BMY 9.5x vs NVS 16.2x Forward P/E) are benchmarked directly in Pillar 4 below.

BMY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$50.0B
Gross Margin70.5%
Op. Margin32.4%
ROE / Fwd P/E44.0% · 9.5x
NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMY CONSOLIDATION
50d in phase · OBV NEUTRAL
Current IV 82.3%
IV Percentile 56th %ile
Put/Call OI Skew 1.29x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMY Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $127.4B market capitalization and 32.4% operating margin.
OpEx & R&D Reinvestment 38.1% of Rev ($19.1B)
90D Engineering Disclosures 0 Published
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published

Investor FAQ BMY vs NVS Key Questions & Quantitative Answers

As of Nov 16, 2026, Bristol-Myers Squibb Co. (BMY) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). BMY carries a Unified Composite Score of 57.3/100 (HOLD) at $63.30 (9.5x Forward P/E, 32.4% operating margin), whereas NVS carries 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin). Technically, BMY sits in a Neutral phase (RSI 55.7, CONSOLIDATION options structure) and NVS sits in a Markup phase (RSI 60.8, UNCLASSIFIED options structure).

BMY leads the Growth & Scale pillar: BMY posts +6.9% YoY revenue growth and -2.8% YoY earnings growth on $50.0B TTM revenue (70.5% gross margin, 32.4% operating margin), compared with NVS at +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin). On trailing 12-month operating scale, BMY generates $50.0B in USD-normalized revenue versus $40.5B for NVS. In operating R&D and SG&A reinvestment, BMY deploys 38.1% of Rev ($19.1B) (0 90-day corporate R&D disclosures) versus 41.2% of Rev ($16.7B) (0 disclosures) for NVS.

BMY screens cheaper on headline valuation multiples. BMY trades at 9.5x Forward P/E, 13.8x Trailing P/E, 17.25x PEG, and 3.3x EV/Revenue (18.6% FCF margin), whereas NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMY (44.0% ROE) versus NVS (24.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BMY carries 82.3% implied volatility (56th %ile, Balanced (25th–60th %ile)), a 1.29x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.17β · 31% Vol realized risk). By comparison, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.